Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02702180 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis
A Phase 2 study, sponsored by Savara.
- Completed
- Registry status
- Phase 2
- Development phase
- 139
- Enrollment target
NCT02702180 is a Phase 2 study that has completed, run by Savara. The registered enrollment target is 139 participants.
The verdict
NCT02702180, a Phase 2 study, has completed, sponsored by Savara.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 139 participants
- Enrollment target
Study Summary
This study evaluates inhaled molgramostim (recombinant human granulocyte macrophage-colony stimulating factor \[rhGM-CSF\]) in the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) patients. A third of the patients will receive inhaled molgramostim once daily for 24 weeks, a third will receive inhaled molgramostim intermittently (7 days on, 7 days off) for 24 weeks and a third will receive inhaled matching placebo for 24 weeks.
Interventions
- DRUG Placebo
- DRUG Molgramostim
- DEVICE PARI eFlow nebulizer system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2016-03-21 |
| Est. Completion | 2019-09-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02702180
The ClinicalTrials.gov registry entry for NCT02702180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Savara, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02702180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02702180 about?
NCT02702180 is a clinical study titled "Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis". This study evaluates inhaled molgramostim (recombinant human granulocyte macrophage-colony stimulating factor \[rhGM-CSF\]) in the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) patients. A third of the patients will receive inhaled molgramostim once daily for 24 weeks, a third will r...
What is the current status of trial NCT02702180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 139 participants. The study started on 2016-03-21. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT02702180?
The interventions under investigation include: Placebo (DRUG), Molgramostim (DRUG), PARI eFlow nebulizer system (DEVICE).
Who is sponsoring clinical trial NCT02702180?
This trial is sponsored by Savara, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.